Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...

These ratings convey expectations for the relative performance of Moderna compared to the broader market. Price Targets: Analysts set price targets as an estimate of a stock's future value.

Moderna’s post-pandemic future was thrown into question Thursday after it disclosed multiple setbacks that disappointed investors. The biotech company has been largely shut out of the COVID ...

Moderna president Stephen Hoge knows investors are waiting to see the company grow in a big way and regain the momentum lost following outsized COVID-19 vaccine revenues.

Moderna and Merck reported data regarding a cutting-edge mRNA-based skin cancer regimen that includes the former’s cancer vaccine, MRNA-4157. Read more here.

Future Outlook for MRNA Stock Moderna will likely perform impressively in the next few quarters, but things should change as we get closer to the business end of 2022.

Trial data will determine the future of this leader in the coronavirus vaccine race. Since that time, Moderna has reported positive interim phase 1 data, and the vaccine candidate recently entered ...

Moderna’s mRNA COVID-19 vaccine candidate was the first U.S. shot to enter late-stage testing, but that doesn’t necessarily mean it has the brightest future of all.

An admittedly hazy outlook So what does the future hold for Moderna? It's definitely complicated, but here's an admittedly hazy outlook. I'm cautiously optimistic that mRNA-1273 will be successful.